Business Wire

Inmarsat, Honeywell Launch World’s Fastest L-band Inflight Connectivity Service for Business Aviation

23.5.2022 11:00:00 EEST | Business Wire | Press release

Share

Inmarsat and Honeywell are setting a new benchmark in satellite communications with the launch of SwiftJet, their latest inflight connectivity service for the business aviation industry. It will enter commercial service in the first half of 2023 and deliver the fastest ever speeds over L-band.

As one of the first new services to be introduced on Inmarsat’s ELERA satellite network, SwiftJet will offer seamless global coverage across flight routes with maximum speeds of 2.6Mbps, up to six times faster than Inmarsat’s existing business aviation connectivity solution over L-band. This will allow passengers to create a secure ‘office in the sky’ with enhanced capabilities for video calls, web browsing, email, texting, cloud-syncing and collaboration tools such as Microsoft Teams. Social media and video applications such as TikTok and YouTube, which were previously challenging over L-band, will also be enabled.

As the latest addition to Inmarsat’s market-leading portfolio of business aviation inflight connectivity services, SwiftJet will be available alongside Jet ConneX (JX) and SwiftBroadband (SBB), which have been activated on thousands of jets worldwide. JX is the most popular and widely-adopted premium, high-speed solution available today, powered by a global constellation of Ka-band satellites. Additionally, SBB offers speeds of 432Kbps over L-band using smaller antennas that are suitable as a secondary system to JX or as primary connectivity for smaller or older aircraft.

SwiftJet uses advanced hardware from Inmarsat’s partner Honeywell, which can be equipped on a broad range of aircraft and also supports cockpit and safety services. Existing customers of Inmarsat’s SBB service will benefit from a natural upgrade path without needing to replace any externally-mounted aircraft equipment, while new customers will experience the same ease of installation as with any Inmarsat L-band terminal. The service also creates new opportunities in the smaller jet market, which have previously been restricted to basic voice or text connectivity that fails to meet the needs of modern day travellers. It is available to pre-order through Honeywell, with additional incentives in an early adopter campaign.

Inmarsat is launching the ground-breaking service at a critical time for the business aviation industry. Following a period of turbulence over the past two years due to the global pandemic, a recent survey by Inmarsat and Corporate Jet Investor (CJI) found that almost 80% of respondents around the world believe more frequent business aviation flights will be taken in the next year. Furthermore, a staggering 90% feel that online activities will dominate the principals’ time in the air, split between business and leisure.

Kai Tang, Inmarsat’s Head of Business Aviation, said: “Inmarsat prides itself on delivering services that meet the unique and fast-evolving requirements of our customers. As the market leader in business aviation connectivity, Inmarsat developed SwiftJet in response to customer and partner feedback for a faster, more advanced L-band offering. They essentially asked us to amplify L-band capabilities without losing its trademark characteristics of resilience, reliability and availability.

“I am proud to say that SwiftJet delivers all of this and more, unlocking exciting new capabilities in the aircraft cabin and allowing users to connect more devices, and enjoy faster connectivity speeds, whenever and wherever they fly. It comes at a time when business aviation travel is not only returning to pre-pandemic levels, but also experiencing unprecedented demand for inflight connectivity.”

Adam Sheppard, Honeywell Aerospace’s Director of Aircraft Connectivity, said: “SwiftJet represents the latest leap forward for inflight connectivity, combining Inmarsat’s commercial satellite capabilities and Honeywell’s connected aircraft expertise to provide scalable, high-speed satellite communications to passengers at 40,000 feet. With Inmarsat we have created a straightforward upgrade path for SwiftBroadband customers, giving them easy access to unprecedented internet speeds over L-band without having to change wiring or antenna hardware.”

Inmarsat’s ELERA global satellite network delivers the world’s most reliable and flexible global connectivity, with full redundancy and unique resilience in all conditions. ELERA capabilities are being further enhanced with the addition of two Inmarsat-6 satellites, the largest and most sophisticated commercial communications satellites ever built, both of which are scheduled to enter service next year and will support SwiftJet through the 2030s, reinforcing the service’s long-term value. The L-band capacity on each I-6 satellite will be substantially greater than Inmarsat’s 4th generation spacecraft, delivering 50% more capacity per beam in addition to unlimited beam routing flexibility.

The I-6 series of satellites will also play a crucial role in the ongoing growth of Inmarsat’s unique ORCHESTRA dynamic mesh network, which will bring existing geosynchronous (GEO) satellites together with low earth orbit satellites (LEO) and terrestrial 5G to form an integrated, high-performance solution, unmatched by any existing or planned competitor offering.

ENDS

ABOUT INMARSAT

Inmarsat is the world leader in global, mobile satellite communications. It owns and operates the world’s most diverse global portfolio of mobile telecommunications satellite networks, and holds a multi-layered, global spectrum portfolio, covering L-band, Ka-band and S-band, enabling unparalleled breadth and diversity in the solutions it provides. Inmarsat’s long-established global distribution network includes not only the world’s leading channel partners but also its own strong direct retail capabilities, enabling end to end customer service assurance.

The company has an unrivalled track record of operating the world’s most reliable global mobile satellite telecommunications networks, sustaining business and mission critical safety & operational applications for more than 40 years. It is also a major driving force behind technological innovation in mobile satellite communications, sustaining its leadership through a substantial investment and a powerful network of technology and manufacturing partners.

Inmarsat operates across a diversified portfolio of sectors with the financial resources to fund its business strategy and holds leading positions in the Maritime, Government, Aviation and Enterprise satcoms markets, operating consistently as a trusted, responsive and high-quality partner to its customers across the globe.

For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.

ABOUT HONEYWELL

Honeywell Aerospace products and services are found on virtually every commercial, defense and space aircraft The Aerospace business unit builds aircraft engines, cockpit and cabin electronics, wireless connectivity systems, mechanical components and more. Its hardware and software solutions create more fuel-efficient aircraft, more direct and on-time flights and safer skies and airports. For more information, visit www.honeywell.com or follow us at @Honeywell_Aero

Honeywell (www.honeywell.com) is a Fortune 100 technology company that delivers industry-specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contacts for media enquiries:

Jonathan Sinnatt/Matthew Knowles
Inmarsat Corporate Communications
Tel: +44 (0)20 7728 1518/1355
press@inmarsat.com

Robeel Haq
Inmarsat Aviation Head of Communications
+44 (0)20 7728 1352
robeel.haq@inmarsat.com

Juliet Collins-Achong
Honeywell
Tel: +44 7787 282932
juliet.collins-achong@honeywell.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye